JP2018150266A - Skin external preparation for preventing and/or improving pimples - Google Patents
Skin external preparation for preventing and/or improving pimples Download PDFInfo
- Publication number
- JP2018150266A JP2018150266A JP2017046975A JP2017046975A JP2018150266A JP 2018150266 A JP2018150266 A JP 2018150266A JP 2017046975 A JP2017046975 A JP 2017046975A JP 2017046975 A JP2017046975 A JP 2017046975A JP 2018150266 A JP2018150266 A JP 2018150266A
- Authority
- JP
- Japan
- Prior art keywords
- zinc sulfate
- sulfate
- acne
- hydrogen carbonate
- sodium hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 88
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 49
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 49
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 49
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims abstract description 46
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 44
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 44
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 20
- 241000555676 Malassezia Species 0.000 claims abstract description 19
- 239000004367 Lipase Substances 0.000 claims abstract description 9
- 102000004882 Lipase Human genes 0.000 claims abstract description 9
- 108090001060 Lipase Proteins 0.000 claims abstract description 9
- 235000019421 lipase Nutrition 0.000 claims abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 229940103272 aluminum potassium sulfate Drugs 0.000 abstract description 6
- 230000002750 inhibitory effect on acne Effects 0.000 abstract 1
- 239000006210 lotion Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- -1 packs Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003788 bath preparation Substances 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001291474 Malassezia globosa Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000907663 Siproeta stelenes Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- RAWGYCTZEBNSTP-UHFFFAOYSA-N aluminum potassium Chemical compound [Al].[K] RAWGYCTZEBNSTP-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムを含有することを特徴とするニキビ予防及び/又は改善用皮膚外用剤である。 The present invention is a skin external preparation for preventing and / or improving acne, characterized by containing zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate.
ニキビは医学的には尋常性ざ瘡と呼ばれており、その炎症にはアクネ菌が関与している。また近年、ニキビの炎症にマラセチアなどのアクネ菌以外の皮膚常在菌も関与していることが明らかとなった(非特許文献1)。アクネ菌やマラセチアが産生するリパーゼは皮脂を分解し、それによって発生した脂肪酸が炎症を引き起こす(非特許文献2、3)。つまり、ニキビの炎症を予防及び/又は改善するためには、アクネ菌やマラセチアの増殖を抑制し、またそれらの微生物が産生するリパーゼの活性を阻害することが重要である。 Acne is medically called acne vulgaris, and acne bacteria are involved in the inflammation. In recent years, it has been revealed that skin resident bacteria other than acne bacteria such as Malassezia are involved in acne inflammation (Non-patent Document 1). The lipase produced by Acne or Malassezia degrades sebum, and the fatty acids generated thereby cause inflammation (Non-patent Documents 2 and 3). That is, in order to prevent and / or improve acne inflammation, it is important to suppress the growth of Acne or Malassezia and to inhibit the activity of lipase produced by these microorganisms.
そのため、ニキビの予防及び/又は改善を目的とし、アクネ菌に対する抗菌剤やリパーゼ阻害剤が多く用いられている(特許文献1、2)。また、マラセチアに対する抗菌剤やリパーゼ阻害剤も多く報告されている(特許文献2、3)。 Therefore, many antibacterial agents and lipase inhibitors against acne are used for the purpose of preventing and / or improving acne (Patent Documents 1 and 2). Many antibacterial agents and lipase inhibitors against malassezia have been reported (Patent Documents 2 and 3).
また、温泉成分にも、ニキビの予防及び/又は改善効果があることが報告されている(特許文献4)。 In addition, it has been reported that hot spring ingredients also have acne prevention and / or improvement effects (Patent Document 4).
しかしながら、これらの成分によるニキビに対する効果は必ずしも十分ではなく、効果の高い、新しい成分の開発が望まれていた。 However, the effects of these ingredients on acne are not always sufficient, and the development of new ingredients with high effects has been desired.
本発明者らは、上記課題の解決に向けた鋭意研究の結果、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分の併用が、アクネ菌及びマラセチアに対する優れた抗菌性と、アクネ菌リパーゼ及びマラセチアリパーゼに対する優れた阻害効果を有することを見出した。さらに、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分を含有した皮膚外用剤に、ニキビに対する予防及び/又は改善効果があることを見出し、本発明を完成するに至った。 As a result of diligent research aimed at solving the above problems, the present inventors have found that the combined use of three components of zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate has excellent antibacterial properties against acne and malassezia, acne lipase and It has been found that it has an excellent inhibitory effect on maraceti alipase. Furthermore, it discovered that the skin external preparation containing three components of zinc sulfate, potassium aluminum sulfate, and sodium hydrogencarbonate had the prevention and / or improvement effect with respect to acne, and came to complete this invention.
本発明で使用する硫酸亜鉛は、硫酸塩泉の成分であり、ZnSO4で表される。製法は特に限定されない。 Zinc sulfate used in the present invention is a component of a sulfate spring and is represented by ZnSO 4 . A manufacturing method is not specifically limited.
本発明で使用する硫酸アルミニウムカリウムは、明礬(ミョウバン)泉の成分であり、AlK(SO4)2で表される。カリウムミョウバン、又はカリミョウバンとも呼ばれる。製法は特に限定されない。 The potassium aluminum sulfate used in the present invention is a component of alum spring and is represented by AlK (SO 4 ) 2 . Also called potassium alum or potash alum. A manufacturing method is not specifically limited.
本発明で使用する炭酸水素ナトリウムは、炭酸水素塩泉の成分であり、NaHCO3で表される。重炭酸ナトリウム、重炭酸ソーダ、又は重曹とも呼ばれる。製法は特に限定されない。 Sodium bicarbonate used in the present invention is a component of a bicarbonate spring and is represented by NaHCO 3 . Also called sodium bicarbonate, sodium bicarbonate, or baking soda. A manufacturing method is not specifically limited.
本発明における硫酸亜鉛の皮膚外用剤(浴用剤を除く)への含有量は、好ましくは0.01〜1重量%である。0.01重量%未満では十分な効果を得にくく、1重量%を超えると効果の増強は小さく、また不経済である。 The content of zinc sulfate in the external preparation for skin (excluding bath preparation) in the present invention is preferably 0.01 to 1% by weight. If the amount is less than 0.01% by weight, it is difficult to obtain a sufficient effect.
本発明における硫酸アルミニウムカリウムの皮膚外用剤(浴用剤を除く)への含有量は、好ましくは0.01〜1重量%である。0.01重量%未満では十分な効果を得にくく、1重量%を超えると効果の増強は小さく、また不経済である。 In the present invention, the content of potassium aluminum sulfate in the external preparation for skin (excluding the bath preparation) is preferably 0.01 to 1% by weight. If the amount is less than 0.01% by weight, it is difficult to obtain a sufficient effect.
本発明における炭酸水素ナトリウムの皮膚外用剤(浴用剤を除く)への含有量は、好ましくは0.01〜1重量%である。0.01重量%未満では十分な効果を得にくく、1重量%を超えると効果の増強は小さく、また不経済である。 The content of sodium bicarbonate in the external preparation for skin (excluding bath preparation) in the present invention is preferably 0.01 to 1% by weight. If the amount is less than 0.01% by weight, it is difficult to obtain a sufficient effect.
本発明の皮膚外用剤には、その効果を損なわない範囲内で、通常の皮膚外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤等の成分を含有することもできる。 In the external preparation for skin of the present invention, fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, which are components used for normal external preparations for skin, within a range that does not impair the effect. It can also contain components such as agents, metal soaps, preservatives, fragrances, humectants, powders, UV absorbers, thickeners, dyes, antioxidants, whitening agents, chelating agents and the like.
本発明において、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムは、化粧品、医薬部外品及び医薬品のいずれにも用いることができ、その剤型としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、軟膏等が挙げられる。 In the present invention, zinc sulfate, aluminum potassium sulfate, and sodium hydrogen carbonate can be used for cosmetics, quasi drugs, and pharmaceuticals. Examples of the dosage form include skin lotions, creams, emulsions, and gels. , Aerosol agents, essences, packs, cleaning agents, bath preparations, foundations, powders, ointments and the like.
硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分の併用は、アクネ菌及びマラセチアに対する優れた抗菌性と、アクネ菌リパーゼ及びマラセチアリパーゼに対する優れた阻害効果を示した。また、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分を含有した皮膚外用剤は、ニキビに対する優れた予防及び/又は改善効果を示した。 The combined use of three components of zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate showed excellent antibacterial activity against acne and malassezia and excellent inhibitory effect against acne lipase and maraceti alipase. Moreover, the skin external preparation containing the three components of zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate showed excellent prevention and / or improvement effects against acne.
次に本発明を詳細に説明するため、実施例として本発明の処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す含有量の部とは重量部を示す。 Next, in order to describe the present invention in detail, examples of formulation and experimental examples of the present invention will be given as examples, but the present invention is not limited thereto. The part of the content shown in the examples indicates parts by weight.
処方例1 クリーム
[処方] 含有量
1.硫酸亜鉛 0.03部
2.硫酸アルミニウムカリウム 0.05
3.炭酸水素ナトリウム 0.1
4.スクワラン 5.5
5.オリーブ油 3.0
6.ステアリン酸 2.0
7.ミツロウ 2.0
8.ミリスチン酸オクチルドデシル 3.5
9.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
10.ベヘニルアルコール 1.5
11.モノステアリン酸グリセリン 2.5
12.香料 0.1
13.1,3−ブチレングリコール 8.5
14.パラオキシ安息香酸エチル 0.05
15.パラオキシ安息香酸メチル 0.2
16.精製水 67.97
[製造方法]成分4〜11を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び13〜16を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃にて成分12を加え、更に30℃まで冷却して製品とする。
Formulation Example 1 Cream [Prescription] Content 1. Zinc sulfate 0.03 parts Potassium aluminum sulfate 0.05
3. Sodium bicarbonate 0.1
4). Squalane 5.5
5. Olive oil 3.0
6). Stearic acid 2.0
7). Beeswax 2.0
8). Octyldodecyl myristate 3.5
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Behenyl alcohol 1.5
11. Glycerol monostearate2.5
12 Fragrance 0.1
13.1,3-Butylene glycol 8.5
14 Ethyl paraoxybenzoate 0.05
15. Methyl paraoxybenzoate 0.2
16. Purified water 67.97
[Manufacturing method] Components 4 to 11 are heated and dissolved and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 13 to 16 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 12 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
処方例2 化粧水
[処方] 含有量
1.硫酸亜鉛 0.02部
2.硫酸アルミニウムカリウム 0.1
3.炭酸水素ナトリウム 0.2
4.1,3−ブチレングリコール 8.0
5.グリセリン 2.0
6.キサンタンガム 0.02
7.クエン酸 0.01
8.クエン酸ナトリウム 0.1
9.エタノール 5.0
10.パラオキシ安息香酸メチル 0.1
11.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
12.香料 0.1
13.精製水 84.25
[製造方法]成分1〜8及び13と、成分9〜12をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 2 Lotion [Prescription] Content 1. Zinc sulfate 0.02 parts Potassium aluminum sulfate 0.1
3. Sodium bicarbonate 0.2
4.1,3-Butylene glycol 8.0
5. Glycerin 2.0
6). Xanthan gum 0.02
7). Citric acid 0.01
8). Sodium citrate 0.1
9. Ethanol 5.0
10. Methyl paraoxybenzoate 0.1
11. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
12 Fragrance 0.1
13. Purified water 84.25
[Production Method] Components 1 to 8 and 13 and Components 9 to 12 are uniformly dissolved, mixed and filtered to obtain a product.
比較例1 化粧水A〜F
処方例2において、成分1〜3を1つ、又は2つを含有し、残りは精製水に置き換えたものを化粧水A〜Fとした。
化粧水A:硫酸亜鉛(成分1)のみ含有
化粧水B:硫酸アルミニウムカリウム(成分2)のみ含有
化粧水C:炭酸水素ナトリウム(成分3)のみ含有
化粧水D:硫酸亜鉛(成分1)及び硫酸アルミニウムカリウム(成分2)のみ含有
化粧水E:硫酸亜鉛(成分1)及び炭酸水素ナトリウム(成分3)のみ含有
化粧水F:硫酸アルミニウムカリウム(成分2)及び炭酸水素ナトリウム(成分3)のみ含有
Comparative Example 1 Lotion A to F
In Formulation Example 2, one or two of components 1 to 3 were contained, and the rest was replaced with purified water as lotions A to F.
Lotion A: Contains only zinc sulfate (component 1) Lotion B: Contains only potassium aluminum sulfate (component 2) Lotion C: Contains only sodium bicarbonate (component 3) D: Zinc sulfate (component 1) and sulfuric acid Contains only aluminum potassium (component 2) lotion E: contains only zinc sulfate (component 1) and sodium hydrogen carbonate (component 3) Lotion F: contains only potassium aluminum sulfate (component 2) and sodium hydrogen carbonate (component 3)
処方例3 乳液
[処方] 含有量
1.硫酸亜鉛 0.03部
2.硫酸アルミニウムカリウム 0.05
3.炭酸水素ナトリウム 0.1
4.スクワラン 5.0
5.オリーブ油 5.0
6.ホホバ油 5.0
7.セタノール 1.5
8.モノステアリン酸グリセリン 2.0
9.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
10.ポリオキシエチレンソルビタンモノオレエート 2.0
(20E.O.)
11.香料 0.1
12.プロピレングリコール 1.0
13.グリセリン 2.0
14.パラオキシ安息香酸メチル 0.2
15.精製水 73.02
[製造方法]成分4〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃にて成分11を加え、更に30℃まで冷却して製品とする。
Formulation Example 3 Emulsion [Prescription] Content 1. Zinc sulfate 0.03 parts Potassium aluminum sulfate 0.05
3. Sodium bicarbonate 0.1
4). Squalane 5.0
5. Olive oil 5.0
6). Jojoba oil 5.0
7). Cetanol 1.5
8). Glycerol monostearate 2.0
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Polyoxyethylene sorbitan monooleate 2.0
(20 EO)
11. Fragrance 0.1
12 Propylene glycol 1.0
13. Glycerin 2.0
14 Methyl paraoxybenzoate 0.2
15. Purified water 73.02
[Manufacturing method] Components 4 to 10 are heated and dissolved, mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 12 to 15 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 11 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
処方例4 ゲル剤
[処方] 含有量
1.硫酸亜鉛 0.03部
2.硫酸アルミニウムカリウム 0.05
3.炭酸水素ナトリウム 0.1
4.エタノール 5.0
5.パラオキシ安息香酸メチル 0.1
6.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
7.香料 0.1
8.1,3−ブチレングリコール 5.0
9.グリセリン 5.0
10.キサンタンガム 0.1
11.カルボキシビニルポリマー 0.2
12.水酸化カリウム 0.2
13.精製水 84.02
[製造方法]成分4〜7と、成分1〜3及び8〜13をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 4 Gel [Prescription] Content 1. Zinc sulfate 0.03 parts Potassium aluminum sulfate 0.05
3. Sodium bicarbonate 0.1
4). Ethanol 5.0
5. Methyl paraoxybenzoate 0.1
6). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
7). Fragrance 0.1
8.1,3-Butylene glycol 5.0
9. Glycerin 5.0
10. Xanthan gum 0.1
11. Carboxyvinyl polymer 0.2
12 Potassium hydroxide 0.2
13. Purified water 84.02
[Manufacturing method] Components 4 to 7 and components 1 to 3 and 8 to 13 are uniformly dissolved and mixed to obtain a product.
処方例5 パック
[処方] 含有量
1.硫酸亜鉛 0.03部
2.硫酸アルミニウムカリウム 0.05
3.炭酸水素ナトリウム 0.1
4.ポリビニルアルコール 12.0
5.エタノール 5.0
6.1,3−ブチレングリコール 8.0
7.パラオキシ安息香酸メチル 0.2
8.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
9.クエン酸 0.1
10.クエン酸ナトリウム 0.3
11.香料 0.1
12.精製水 73.62
[製造方法]成分1〜12を均一に溶解し製品とする。
Formulation Example 5 Pack [Prescription] Content 1. Zinc sulfate 0.03 parts Potassium aluminum sulfate 0.05
3. Sodium bicarbonate 0.1
4). Polyvinyl alcohol 12.0
5. Ethanol 5.0
6.1,3-Butylene glycol 8.0
7). Methyl paraoxybenzoate 0.2
8). Polyoxyethylene hydrogenated castor oil (20 EO) 0.5
9. Citric acid 0.1
10. Sodium citrate 0.3
11. Fragrance 0.1
12 Purified water 73.62
[Production Method] Components 1 to 12 are uniformly dissolved to obtain a product.
処方例6 ファンデーション
[処方] 含有量
1.硫酸亜鉛 0.02部
2.硫酸アルミニウムカリウム 0.1
3.炭酸水素ナトリウム 0.2
4.炭酸ナトリウム 0.1
5.ステアリン酸 2.4
6.ポリオキシエチレンソルビタンモノステアレート 1.0
(20E.O.)
7.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
8.セタノール 1.0
9.液状ラノリン 2.0
10.流動パラフィン 3.0
11.ミリスチン酸イソプロピル 6.5
12.パラオキシ安息香酸ブチル 0.1
13.カルボキシメチルセルロースナトリウム 0.1
14.ベントナイト 0.5
15.プロピレングリコール 4.0
16.トリエタノールアミン 1.1
17.パラオキシ安息香酸メチル 0.2
18.二酸化チタン 8.0
19.タルク 4.0
20.ベンガラ 1.0
21.黄酸化鉄 2.0
22.香料 0.1
23.精製水 60.58
[製造方法]成分5〜12を加熱溶解し、80℃に保ち油相とする。成分23に成分13をよく膨潤させ、続いて、成分1〜4及び14〜17を加えて均一に混合する。これに粉砕機にて粉砕混合した成分18〜21を加え、ホモミキサーにて撹拌し、75℃に保ち水相とする。この水相に油相をかき混ぜながら加え、冷却し、45℃にて成分22を加え、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 6 Foundation [Prescription] Content 1. Zinc sulfate 0.02 parts Potassium aluminum sulfate 0.1
3. Sodium bicarbonate 0.2
4). Sodium carbonate 0.1
5. Stearic acid 2.4
6). Polyoxyethylene sorbitan monostearate 1.0
(20 EO)
7). Polyoxyethylene cetyl ether (20E.O.) 2.0
8). Cetanol 1.0
9. Liquid lanolin 2.0
10. Liquid paraffin 3.0
11. Isopropyl myristate 6.5
12 Butyl paraoxybenzoate 0.1
13. Sodium carboxymethylcellulose 0.1
14 Bentonite 0.5
15. Propylene glycol 4.0
16. Triethanolamine 1.1
17. Methyl paraoxybenzoate 0.2
18. Titanium dioxide 8.0
19. Talc 4.0
20. Bengala 1.0
21. Yellow iron oxide 2.0
22. Fragrance 0.1
23. Purified water 60.58
[Manufacturing method] Components 5 to 12 are dissolved by heating and kept at 80 ° C to obtain an oil phase. Swell component 13 well in component 23, then add components 1-4 and 14-17 and mix uniformly. To this, components 18 to 21 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oily phase is added to the aqueous phase while stirring, cooled, component 22 is added at 45 ° C., and cooled to 30 ° C. with stirring to give a product.
処方例7 浴用剤
[処方] 含有量
1.硫酸亜鉛 5.0部
2.硫酸アルミニウムカリウム 5.0
3.炭酸水素ナトリウム 45.0
4.黄色202号(1) 0.1
5.香料 0.1
6.無水硫酸ナトリウム 44.8
[製造方法]成分1〜6を均一に混合し製品とする。
Formulation Example 7 Bath Agent [Prescription] Content 1. Zinc sulfate 5.0 parts2. Potassium aluminum sulfate 5.0
3. Sodium bicarbonate 45.0
4). Yellow No. 202 (1) 0.1
5. Fragrance 0.1
6). Anhydrous sodium sulfate 44.8
[Production Method] Components 1 to 6 are uniformly mixed to obtain a product.
次に、本発明の効果を詳細に説明するため、実験例を挙げる。 Next, experimental examples will be given to explain the effects of the present invention in detail.
実験例1 抗菌力試験
日本化学療法学会標準法のカンテン平板希釈法に準じて、アクネ菌(Propionibacterium acnes JCM 6425)及びマラセチア(Malasezzia globosa NBRC 101597)に対する硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの最小発育阻止濃度(MIC、μg/mL)を測定した。すなわち、各成分を16〜16000μg/mL(公比2)となるように加えた培地を用い、アクネ菌及びマラセチアの増殖性を検討した。培地としては、アクネ菌については変法GAM寒天培地(日水製薬)、マラセチアについてはLeeming&Notman agar培地(J Clin Microbiol,Vol.25,PP.2017−2019,1987)を用いた。アクネ菌は、35℃、嫌気条件にて5日間培養した。マラセチアは、32.5℃にて12日間培養した。
Experimental Example 1 Antibacterial activity test According to the standard plate dilution method of the Japanese Society of Chemotherapy, the minimum of zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate against Acne bacteria (Propionibacterium acnes JCM 6425) and Malassezia (Malazezia globosa NBRC 101597) The growth inhibitory concentration (MIC, μg / mL) was measured. That is, using the culture medium which added each component so that it might become 16-16000 microgram / mL (common ratio 2), the growth property of the acne bacteria and the Malassezia was examined. As the medium, modified GAM agar medium (Nissui Pharmaceutical) was used for acne, and Leeming & Notman agar medium (J Clin Microbiol, Vol. 25, PP. 2017-2019, 1987) was used for malassezia. Acne bacteria were cultured at 35 ° C. under anaerobic conditions for 5 days. Malassezia was cultured at 32.5 ° C. for 12 days.
各成分のアクネ菌に対する抗菌性を表1に示す。 Table 1 shows the antibacterial properties of each component against acne bacteria.
アクネ菌に対するMICは、硫酸亜鉛単独では500μg/mL(No.1)、硫酸アルミニウムカリウム単独では8000μg/mL(No.2)、炭酸水素ナトリウム単独では16000μg/mL(No.3)であった。2成分併用の場合、硫酸亜鉛:250μg/mLと硫酸アルミニウムカリウム:4000μg/mL(No.4)、硫酸亜鉛:250μg/mLと炭酸水素ナトリウム:8000μg/mL(No.5)、硫酸亜鉛:125μg/mLと硫酸アルミニウムカリウム:8000μg/mL(No.6)、硫酸亜鉛:125μg/mLと炭酸水素ナトリウム:16000μg/mL(No.7)であり、効果は相加的であった。3成分併用の場合、硫酸亜鉛:250μg/mLと硫酸アルミニウムカリウム:500μg/mLと炭酸水素ナトリウム:1000μg(No.8)、硫酸亜鉛:125μg/mLと硫酸アルミニウムカリウム:1000μg/mLと炭酸水素ナトリウム:2000μg(No.9)、硫酸亜鉛:63μg/mLと硫酸アルミニウムカリウム:2000μg/mLと炭酸水素ナトリウム:4000μg(No.10)であり、相乗的な効果が認められた。 The MIC for acne bacteria was 500 μg / mL (No. 1) for zinc sulfate alone, 8000 μg / mL (No. 2) for potassium aluminum sulfate alone, and 16000 μg / mL (No. 3) for sodium bicarbonate alone. In the case of two-component combination, zinc sulfate: 250 μg / mL and potassium aluminum sulfate: 4000 μg / mL (No. 4), zinc sulfate: 250 μg / mL and sodium hydrogen carbonate: 8000 μg / mL (No. 5), zinc sulfate: 125 μg / ML and potassium aluminum sulfate: 8000 μg / mL (No. 6), zinc sulfate: 125 μg / mL and sodium hydrogen carbonate: 16000 μg / mL (No. 7), and the effects were additive. In the case of the three-component combination, zinc sulfate: 250 μg / mL, potassium aluminum sulfate: 500 μg / mL, sodium hydrogen carbonate: 1000 μg (No. 8), zinc sulfate: 125 μg / mL, potassium aluminum sulfate: 1000 μg / mL, and sodium hydrogen carbonate : 2000 μg (No. 9), zinc sulfate: 63 μg / mL, aluminum potassium sulfate: 2000 μg / mL, and sodium hydrogen carbonate: 4000 μg (No. 10), and a synergistic effect was observed.
各成分のマラセチアに対する抗菌性を表2に示す。 Table 2 shows the antibacterial properties of each component against malassezia.
マラセチアに対するMICは、硫酸亜鉛単独では125μg/mL(No.1)、硫酸アルミニウムカリウム単独では500μg/mL(No.2)、炭酸水素ナトリウム単独では1000μg/mL(No.3)であった。2成分併用の場合、硫酸亜鉛:63μg/mLと硫酸アルミニウムカリウム:250μg/mL(No.4)、硫酸亜鉛:63μg/mLと炭酸水素ナトリウム:500μg/mL(No.5)、硫酸亜鉛:32μg/mLと硫酸アルミニウムカリウム:500μg/mL(No.6)、硫酸亜鉛:32μg/mLと炭酸水素ナトリウム:1000μg/mL(No.7)であり、効果は相加的であった。3成分併用の場合、硫酸亜鉛:63μg/mLと硫酸アルミニウムカリウム:32μg/mLと炭酸水素ナトリウム:63μg(No.8)、硫酸亜鉛:32μg/mLと硫酸アルミニウムカリウム:63μg/mLと炭酸水素ナトリウム:125μg(No.9)、硫酸亜鉛:16μg/mLと硫酸アルミニウムカリウム:125μg/mLと炭酸水素ナトリウム:250μg(No.10)であり、相乗的な効果が認められた。 The MIC for Malassezia was 125 μg / mL (No. 1) for zinc sulfate alone, 500 μg / mL (No. 2) for potassium aluminum sulfate alone, and 1000 μg / mL (No. 3) for sodium bicarbonate alone. In the case of two-component combination, zinc sulfate: 63 μg / mL and potassium aluminum sulfate: 250 μg / mL (No. 4), zinc sulfate: 63 μg / mL and sodium hydrogen carbonate: 500 μg / mL (No. 5), zinc sulfate: 32 μg / ML and potassium aluminum sulfate: 500 μg / mL (No. 6), zinc sulfate: 32 μg / mL and sodium hydrogen carbonate: 1000 μg / mL (No. 7), and the effects were additive. In the case of three-component combination, zinc sulfate: 63 μg / mL, potassium aluminum sulfate: 32 μg / mL, sodium hydrogen carbonate: 63 μg (No. 8), zinc sulfate: 32 μg / mL, potassium aluminum sulfate: 63 μg / mL, and sodium hydrogen carbonate : 125 μg (No. 9), zinc sulfate: 16 μg / mL, potassium aluminum sulfate: 125 μg / mL, and sodium bicarbonate: 250 μg (No. 10), and a synergistic effect was observed.
実験例2 リパーゼ活性阻害試験
文献(日皮会誌,115,2381−2388,2005)に準じて、アクネ菌(Propionibacterium acnes JCM 6425)及びマラセチア(Malasezzia globosa NBRC 101597)に対する硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムのリパーゼ活性の阻害効果を測定した。アクネ菌については、ブレインハートインヒュージョン培地(栄研化学)を用い、嫌気条件、35℃にて48時間培養した培養物を15000rpm、10分間遠心分離し、得られた上清をアクネ菌リパーゼ液とした。マラセチアについては、Leeming&Notman ager培地を用い、32.5℃にて72時間培養した培養物を、Mcllvaine buffer(pH5.0)に分散し、マラセチアリパーゼ液とした。4.0重量%の硫酸亜鉛、硫酸アルミニウムカリウム又は炭酸水素ナトリウムを含むMcllvaine buffer(アクネ菌:pH7.4、マラセチア:pH5.0)50μLとリパーゼ液50μLを96穴ウェルプレート内で混和後、35℃にて30分間インキュベートした。次に、0.01mM 4−メチルウンベリフェロンオレートを含むMcllvaine bufferを100μL加え、35℃にて30分間インキュベートした。その後、アクネ菌リパーゼについては、マイクロプレートリーダーにて蛍光強度を測定した(Ex:320nm、Em:450nm)。マラセチアリパーゼについては、2000rpmで10分間遠心分離し、得られた上清100μLを新しい96穴ウェルプレートに移し、蛍光強度を測定した。試料を添加しなかった場合の蛍光強度を100として、リパーゼ活性阻害率(%)を求めた。
Experimental Example 2 Lipase Activity Inhibition Test Zinc sulfate, potassium aluminum sulfate and carbonate for Acne (Propionibacterium acnes JCM 6425) and Malassezia (Malassezia globosa NBRC 101597) according to the literature (Hichikaikai, 115, 2381-2388, 2005) The inhibitory effect of sodium hydrogen lipase activity was measured. For acne bacteria, brain heart infusion medium (Eiken Chemical Co., Ltd.) was used, and the culture cultured at 35 ° C. for 48 hours under anaerobic conditions was centrifuged at 15000 rpm for 10 minutes. It was. For malassezia, a culture cultured for 72 hours at 32.5 ° C. using Leeming & Notman ager medium was dispersed in Mclvine buffer (pH 5.0) to obtain a maraceti alipase solution. After mixing 50 μL of Mclvaine buffer (Acne bacteria: pH 7.4, Malassezia: pH 5.0) containing 4.0% by weight of zinc sulfate, potassium aluminum sulfate or sodium bicarbonate in a 96-well plate, 35 Incubated for 30 minutes at ° C. Next, 100 μL of Mclvaine buffer containing 0.01 mM 4-methylumbelliferone oleate was added and incubated at 35 ° C. for 30 minutes. Thereafter, the fluorescence intensity of Acne lipase was measured with a microplate reader (Ex: 320 nm, Em: 450 nm). For maraceti alipase, centrifugation was performed at 2000 rpm for 10 minutes, and 100 μL of the obtained supernatant was transferred to a new 96-well plate, and the fluorescence intensity was measured. The inhibition rate (%) of lipase activity was determined with the fluorescence intensity when the sample was not added as 100.
各成分のアクネ菌リパーゼに対する阻害効果を表3に示す。 Table 3 shows the inhibitory effect of each component on Acne lipase.
3成分を併用した場合、アクネ菌リパーゼ活性阻害率は相乗的に上昇した。 When the three components were used in combination, the rate of inhibition of Acne lipase activity increased synergistically.
各成分のマラセチアリパーゼに対する阻害効果を表4に示す。 Table 4 shows the inhibitory effects of each component on malachite alipase.
3成分を併用した場合、マラセチアリパーゼ活性阻害率は相乗的に上昇した。 When the three components were used in combination, the malase thiolipase activity inhibition rate increased synergistically.
実験例3 ニキビの予防及び/又は改善効果
実施例1の化粧水、比較例1の化粧水A〜Fを用いて、ニキビに悩む女性70人(20〜44才、各化粧水当たり10人)を対象に1ヶ月間の使用試験を行った。使用後、アンケート調査によりニキビの予防及び改善について判定した。
Experimental Example 3 Acne Prevention and / or Improvement Effects 70 women suffering from acne using the lotion of Example 1 and the lotions A to F of Comparative Example 1 (20 to 44 years old, 10 per each lotion) A one-month use test was conducted on the subjects. After use, the prevention and improvement of acne were determined by questionnaire survey.
結果を表5に示す。 The results are shown in Table 5.
表5の結果から、硫酸亜鉛、硫酸アルミニウムカリウム又は炭酸水素ナトリウムのいずれか1つ、又は2つを併用した比較例1の化粧水A〜Fと比べて、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3つを併用した実施例2の化粧水は、優れたニキビの予防及び改善効果を示した。なお、試験期間中皮膚トラブルは1人もなく、安全性においても問題なかった。 From the results of Table 5, zinc sulfate, potassium aluminum sulfate and hydrogen carbonate compared to lotions A to F of Comparative Example 1 using either one of zinc sulfate, potassium aluminum sulfate or sodium hydrogen carbonate, or two in combination. The lotion of Example 2 using three of sodium in combination showed excellent acne prevention and improvement effects. In addition, there was no skin problem during the test period, and there was no problem in safety.
実施例1、及び3〜7で得られた皮膚外用剤についても同様に使用試験を行った結果、いずれも十分なニキビの予防及び/又は改善効果を示した。また、試験期間中皮膚トラブルは1人もなく、安全性においても問題なかった。 As a result of conducting a use test on the skin external preparations obtained in Examples 1 and 3 to 7 as well, all of them showed sufficient acne prevention and / or improvement effects. In addition, there was no skin trouble during the test period, and there was no problem in safety.
以上のことから、本発明の硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分の併用は、ニキビ原因菌であるアクネ菌及びマラセチアに対し、相乗的な優れた抗菌効果及びリパーゼ活性阻害効果を示した。また、硫酸亜鉛、硫酸アルミニウムカリウム及び炭酸水素ナトリウムの3成分を併用した皮膚外用剤は、優れたニキビの予防及び/又は改善効果を示した。 From the above, the combined use of the three components of zinc sulfate, potassium aluminum sulfate and sodium bicarbonate of the present invention has a synergistic excellent antibacterial effect and lipase activity inhibitory effect against acne and malassezia, which are acne-causing bacteria. Indicated. Moreover, the skin external preparation which used together three components of zinc sulfate, potassium aluminum sulfate, and sodium hydrogencarbonate showed the prevention and / or improvement effect of the outstanding acne.
本発明の硫酸亜鉛、硫酸アルミニウムカリウム、及び炭酸水素ナトリウムを含有することを特徴とする皮膚外用剤は、ニキビの予防及び/又は改善を目的とする化粧品、医薬部外品及び医薬品に利用可能である。
The topical skin preparation containing zinc sulfate, potassium aluminum sulfate, and sodium hydrogen carbonate according to the present invention can be used for cosmetics, quasi drugs, and pharmaceuticals for the purpose of preventing and / or improving acne. is there.
Claims (3)
A skin external preparation for preventing and / or improving acne, characterized by containing zinc sulfate, potassium aluminum sulfate and sodium hydrogen carbonate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017046975A JP6840324B2 (en) | 2017-03-13 | 2017-03-13 | Topical skin for acne prevention and / or improvement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017046975A JP6840324B2 (en) | 2017-03-13 | 2017-03-13 | Topical skin for acne prevention and / or improvement |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018150266A true JP2018150266A (en) | 2018-09-27 |
JP6840324B2 JP6840324B2 (en) | 2021-03-10 |
Family
ID=63680037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017046975A Active JP6840324B2 (en) | 2017-03-13 | 2017-03-13 | Topical skin for acne prevention and / or improvement |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6840324B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020111529A (en) * | 2019-01-10 | 2020-07-27 | 日本メナード化粧品株式会社 | Scalp and hair cosmetic for prevention and/or improvement of dandruff and/or itching of scalp |
WO2022254289A1 (en) * | 2021-06-04 | 2022-12-08 | 花王株式会社 | Hydrogel |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02111714A (en) * | 1988-10-20 | 1990-04-24 | Nonogawa Shoji:Kk | Cosmetic |
JP2003503333A (en) * | 1999-06-25 | 2003-01-28 | ザ、プロクター、エンド、ギャンブル、カンパニー | Antimicrobial composition for topical use |
WO2003082229A1 (en) * | 2002-03-29 | 2003-10-09 | Shiseido Co., Ltd. | Composite powder and cosmetic containing the same |
JP2005185103A (en) * | 2003-12-03 | 2005-07-14 | Nippon Menaade Keshohin Kk | Skin care preparation for external use |
JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
-
2017
- 2017-03-13 JP JP2017046975A patent/JP6840324B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02111714A (en) * | 1988-10-20 | 1990-04-24 | Nonogawa Shoji:Kk | Cosmetic |
JP2003503333A (en) * | 1999-06-25 | 2003-01-28 | ザ、プロクター、エンド、ギャンブル、カンパニー | Antimicrobial composition for topical use |
WO2003082229A1 (en) * | 2002-03-29 | 2003-10-09 | Shiseido Co., Ltd. | Composite powder and cosmetic containing the same |
JP2005185103A (en) * | 2003-12-03 | 2005-07-14 | Nippon Menaade Keshohin Kk | Skin care preparation for external use |
JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020111529A (en) * | 2019-01-10 | 2020-07-27 | 日本メナード化粧品株式会社 | Scalp and hair cosmetic for prevention and/or improvement of dandruff and/or itching of scalp |
JP7168212B2 (en) | 2019-01-10 | 2022-11-09 | 日本メナード化粧品株式会社 | Scalp and hair cosmetic for prevention and improvement of dandruff and/or itching of the scalp |
WO2022254289A1 (en) * | 2021-06-04 | 2022-12-08 | 花王株式会社 | Hydrogel |
Also Published As
Publication number | Publication date |
---|---|
JP6840324B2 (en) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050100621A1 (en) | Dermatological compositions | |
JP5013753B2 (en) | Antiseptic disinfectant composition | |
KR101851010B1 (en) | Compositions for the antiinflammatory and the antimicrobial activities | |
JP5774884B2 (en) | Acne bacteria biofilm formation inhibitor | |
JP4828126B2 (en) | Antibacterial agent | |
JP6840324B2 (en) | Topical skin for acne prevention and / or improvement | |
JP5840437B2 (en) | Anti-inflammatory agent | |
JP5748996B2 (en) | Topical skin preparation | |
JP2002326942A (en) | Preparation for external use for skin | |
WO2015064681A1 (en) | Composition for external use | |
WO1998052516A1 (en) | Scalp care compositions | |
JP2006298814A (en) | Skin lotion for acne | |
WO2018084112A1 (en) | Acne strain-selective antibacterial agent | |
JP2015178494A (en) | water-in-oil emulsion composition | |
JP2005206521A (en) | Antimicrobial agent | |
US20060264505A1 (en) | Dermatological compositions | |
JP4842550B2 (en) | Tyrosinase activity inhibitor, melanin production inhibitor, and skin whitening external preparation | |
JP2011207808A (en) | Antibacterial agent | |
JP2007161654A (en) | Antiseptic microbicide, cosmetic or medicine comprising the same antiseptic microbicide formulated therein and antiseptic microbicidal method | |
JP2016113394A (en) | Ascorbic acid derivative or its salt and cosmetic | |
JP7168212B2 (en) | Scalp and hair cosmetic for prevention and improvement of dandruff and/or itching of the scalp | |
JP6661292B2 (en) | Peroxidation inhibitors for lipids and cosmetics for scalp hair | |
JP2017186329A (en) | Skin pigmentation inhibitor | |
JP6209350B2 (en) | Acne control composition, external preparation for skin and cosmetics | |
KR102038366B1 (en) | Cosmetic composition for improving acne skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200110 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200923 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6840324 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |